Policy BO that undue or excessive imports do not adversely affect genuine interests of indigenous producers.

Manufacture of Drugs with Foreign **Equity Holding**

1301. SHRI SHANKARRAO NARA-YANRAO (DESHMUKH: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) number of companies having foreign equity more than 26 per cent which «re manufacturing drugs in the country alongwith names and percent age of equity holding by each,
- (b) whether it is a fact that his Ministry is not monitoring imports and exports made by individual company;
- (c) whether it is also a fact that these companies are importing raw materials from their principals at very high prices and exporting at very low prices?
- (d) if so, what system has been adapted by his Miinstry to check up overinvoicing/under-invoicing and

transfer of pacing by these companies;

to Questions

(e) names of major bulk drugs and drug intermediates imported by these companies "from their principals and their associates during last three years. year-wise alongwith quantity and CIF Price?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEEREN-DRA PATEL): (a) The relevant in formation to the extent available is given i)n the endoibed Statement, (See below;)

- (b) to (d) [Imports and exports made by individual companies are not regularly monitored. However, whenever any specific complaints about over^invoidng/under-invoiding, transfer pricing and irregular imports, etc against individual companies are received, these are looked into and appropriate action is taken in the matter in consultation with other Ministries/Departments involved.
- (e) Information, to the extent possible would be collected and laid on the Table of the House.

Statement List of drug companies having direct foreign equity of 26% and above.

SI. No.	Name of compary		,		Percentage of direct foreign equity holding	Remarks, if any		
1		2					3	4
1	M/s. Smith Kline & French	•		•	-		100 (E	ranch) Diluting to 40%
	M/s. Hindustan Ciba-Geigy.						51	
. 3	M/s. Hoechst Pharmaceuticals						50	
. 4	M/s. Bayer (India) Limited			. •		•	51	
	M/s. Johnson & Johnson	, <u>•</u> :					75	Representation
. (M/s. Cyanamid.	* 12 * 12	•.	•.		•	5.5	, 5- · · · · · · · · · · · · · · · · · ·
7	M/s. Alkali Chemicals Corpora	tion (of Ir	ıdis (II	FL)		51	
	M/s. Pfizer						60	•

209	Written Answers	[13 MAY	1985],		to Ques	stions	210
1	2				. 3		4
10 A	l/s. Boots Go. (I) Ltd 1/s. Sandoz. 1/s. Wyeth Laboratories.		•		53 60 74	· ,	
13 N	 Burroughs Wellcome, Merk Sharp & Dohm 	e	•	• . •	6о	Diluting to	
	L/s. Roche Products M/s. Richardson Hindusta		•	• •		Diluting to	74%
•	M/s. E. Merck.		•	• •	40		
	M/s. Uni-Sankyo.	• • •	•		.51	÷ ·	
-	M/s. Anglo French Drug	Co (T) Ltd	•		49		
	M/s. Carter Wallace Limi	• •	•	•	40		
_	M/s. C.E. Fulford .		•		40	•	44 5 44
	M/s. Abbott Laboratories	(I) Put. Lid			÷ , 40		:
	M/s. Geoffrey Manners &	• •	•				iş F
	M/s. J.L. Morison Son &			•	40 40		*,
_	M/s. Milles India Limited	• • •			40	/	- 13 d.
•	M/s. Mc-Gaw-Ravindra				40	, ;	
-	M/s. Wander Limited.				. 40		
	M/s, H.M.M. Limited.				. 40		. 14.
,	M/s. Sybiotics Limited.				40		(i)
29	M/s. UNI UCB (I) Ivi.	ાતન .			40		
30	M/s. Galxo Laboratories				40	7	*
31	M/s. Warner Hindustam	•		•.	. 40	•	- 1 1 - 1
32	M/s. May & Baker (I) L	id					
33	M/s. Parke Davis (I) Ltd	l			. 40		· • .
34	Ms. Nicholas Laborator		td.	•	39*9	• .	
35	M/s, Reckitt & Goleman	of (I) Led.			. 39*9		•
36	M/s. Duphar Interfram				. 39°9		
37	M/s. Scarle India Limit	ed .			39	•	
38	M/s. Bochringer Knoll l	Limited.			. 38-4	0	
39	M/s, German Remedies	Limited.			. 38-2	2	
40	M/s. Roussel Pharmacer	uticals Ltd.		•	. 33*3	3	
41	M/s, Curewel (1) Ltd.				. 32.5	4	
42	M/s. Cibatul Limited.	•				ţo.	
43	M/s. Rallies India Limi	ted.		· .	. 30.	94	•
. 44	M/s. Infar India Limite	.aī				<u> 1</u> 0 .	